Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifampicin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days |
| Name | Type | Description |
|---|---|---|
| Rifampicin | DRUG | 11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin. |
| Midazolam | DRUG | 2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam |
| BAY1002670_Vilaprisan | DRUG | 2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan |
Inclusion Criteria: * Healthy female postmenopausal subjects * Age: 45 to 65 years (inclusive) * Body mass index (BMI) : ≥20 and ≤32 kg/m² * Race: White Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinica...
Rifampicin is a small molecule being investigated for use in endometriosis. It is currently in Phase 1 clinical development. The drug is being studied in a drug-drug interaction trial with vilaprisan, which has been completed. Rifampicin is not approved for this indication and remains investigational.
Rifampicin is a small molecule antibiotic that works by inhibiting bacterial DNA-dependent RNA polymerase. However, its mechanism of action in the context of endometriosis is not specified. The drug is being studied for its potential effects in this condition, but the specific molecular target in endometriosis has not been disclosed.
Rifampicin is being developed by Bayer AG, a German pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market. The company is conducting clinical research on Rifampicin for the treatment of endometriosis.
Rifampicin is in Phase 1 clinical development for endometriosis. It is an investigational drug and has not been approved by regulatory authorities for this indication. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical research.
Rifampicin has one completed clinical trial, NCT02975440, titled 'Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan'. This Phase 1 trial enrolled 12 female participants aged 45 years and older in Germany. The study was uncontrolled and not randomized or double-blinded.
Rifampicin is also known as rifampin in some regions. It is a well-established antibiotic used to treat various bacterial infections, including tuberculosis. However, its use in endometriosis is investigational and not yet approved. The drug is being studied for potential new applications beyond its established antibiotic use.